IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)

A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated With Risedronate.

The primary objective of this study is to assess the impact of physician's reinforcement using bone marker data on the subject's compliance (at least 50% drug taken) and persistence on treatment after one year in postmenopausal osteoporotic women.

Inclusion Criteria:

• Ambulatory women,
• Caucasian, Oriental or Multiracial
• not previously diagnosed for osteoporosis.

Exclusion Criteria:

• Females of black descent and for the US african american are excluded because of the very low incidence of postmenopausal osteoporosis
• and having used oral or parenteral glucocorticoids (>= 5 mg prednisone or equivalent per day) within 3 months of starting study drug or for more than one month within six months prior to study entry.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.